Medtronic reported a 3 percent rise in overall revenue in the second fiscal quarter despite ongoing challenges with its heart and spine implants, according to a Washington Post report.
Sales of the company's spinal implants and heart defibrillators, which account for about 40 percent of total sales, had been weak for more than a year and were down 5 percent this quarter as well. Overall revenue reached $4.13 billion and was boosted by sales of heart valves, stents and other upgraded products.
Related Articles on Medical Devices:
FDA Clears Aptus Endosystems EndoStapling System
Doctors Question the Value of Robot-Assisted Surgery
FDA Studying New Heart Stents that Stretch After Implantation
Sales of the company's spinal implants and heart defibrillators, which account for about 40 percent of total sales, had been weak for more than a year and were down 5 percent this quarter as well. Overall revenue reached $4.13 billion and was boosted by sales of heart valves, stents and other upgraded products.
Related Articles on Medical Devices:
FDA Clears Aptus Endosystems EndoStapling System
Doctors Question the Value of Robot-Assisted Surgery
FDA Studying New Heart Stents that Stretch After Implantation